Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 309

    1.

    Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.

    Gomez-Reino JJ, Carmona L; BIOBADASER Group.

    Arthritis Res Ther. 2006;8(1):R29. Epub 2006 Jan 6.

    PMID:
    16507128
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

    Arthritis Rheum. 2007 Jan;56(1):13-20.

    PMID:
    17195186
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

    JAMA. 2009 Feb 18;301(7):737-44.

    PMID:
    19224750
    [PubMed - indexed for MEDLINE]
    4.

    Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.

    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.

    Ann Rheum Dis. 2009 Apr;68(4):552-7. Epub 2008 May 8.

    PMID:
    18467515
    [PubMed - indexed for MEDLINE]
    5.

    Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

    Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register.

    Arthritis Res Ther. 2009;11(2):R52. Epub 2009 Apr 8.

    PMID:
    19356232
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.

    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.

    Ann Rheum Dis. 2007 Oct;66(10):1393-7. Epub 2007 Jul 5.

    PMID:
    17613555
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.

    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.

    Arthritis Rheum. 2008 Feb 15;59(2):234-40.

    PMID:
    18240258
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

    J Rheumatol. 2011 Jul;38(7):1273-81. Epub 2011 May 15.

    PMID:
    21572150
    [PubMed - indexed for MEDLINE]
    9.

    TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.

    Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG.

    Ann N Y Acad Sci. 2009 Sep;1173:837-46.

    PMID:
    19758236
    [PubMed - indexed for MEDLINE]
    10.

    Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

    Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

    Arthritis Rheum. 2008 Mar;58(3):667-77.

    PMID:
    18311816
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

    Carmona L, Gómez-Reino JJ; BIOBADASER Group.

    Arthritis Res Ther. 2006;8(3):R72. Epub 2006 Apr 18.

    PMID:
    16620398
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

    Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group.

    Arthritis Rheum. 2009 Jul;60(7):1884-94. Erratum in: Arthritis Rheum. 2009 Aug;60(8):2540. Lorthololary, O [corrected to Lortholary, O].

    PMID:
    19565495
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

    Arthritis Rheum. 2009 Nov;60(11):3180-9.

    PMID:
    19877027
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

    Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians.

    Ann Rheum Dis. 2006 Jun;65(6):746-52. Epub 2005 Dec 8.

    PMID:
    16339288
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

    Arthritis Rheum. 2009 May 15;61(5):560-8.

    PMID:
    19405000
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

    Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group.

    Arthritis Rheum. 2003 Aug;48(8):2122-7.

    PMID:
    12905464
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

    Fleischmann R, Iqbal I.

    Drugs Aging. 2007;24(3):239-54. Review.

    PMID:
    17362051
    [PubMed - indexed for MEDLINE]
    19.

    Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.

    Haberhauer G, Strehblow C, Fasching P.

    Wien Med Wochenschr. 2010 May;160(9-10):220-4.

    PMID:
    20632149
    [PubMed - indexed for MEDLINE]
    20.

    Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.

    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.

    Scand J Rheumatol. 2005 Sep-Oct;34(5):353-8.

    PMID:
    16234182
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk